Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 73INDUSTRY 39NIH 6NETWORK 5OTHER_GOV 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Pathologic Complete Response 1

Interventions

Capecitabine 9Bevacizumab 8tislelizumab 7Oxaliplatin 7Drug Therapy 7pembrolizumab 6Surgical Procedures, Operative 6Cisplatin 6Standard of Care 5Radiotherapy 5Laparoscopy 5Fluorouracil 5Docetaxel 5Carboplatin 5toripalimab 4Radiosurgery 4Leucovorin 4Exercise 4Epirubicin 4Cyclophosphamide 4pertuzumab 3durvalumab 3dalpiciclib 3atezolizumab 3anlotinib 3Saline Solution 3Rituximab 3Radiation 3Prednisone 3Population Groups 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER_GOV × pertuzumab × 1 year × Clear all
NCT07057427 2025-07-09

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Henan Cancer Hospital

Phase 3 Recruiting
812 enrolled
Breast

Breast Neoplasms

NCT07047755 2025-07-02

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Not yet recruiting
48 enrolled
Breast

Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡